CANNAINVESTOR Magazine U.S. Publicly-Traded Companies November 2017 | Page 62

Lexaria Bioscience Corp .
Lexaria Bioscience P E R F O R M • R E C O V E R

Lexaria Bioscience Corp .

CSE : LXX | OTCQB : LXRP
Lexaria Bioscience Corp . is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds . The Company ’ s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids , while also masking taste . Cannabinoids are poorly absorbed by the body ’ s gastrointestinal tract and consumers often default to alternate routes of administration like smoking to achieve higher effectiveness .
The Company ’ s technology is patent-protected for cannabidiol ( CBD ) and all other non-psychoactive cannabinoids , and patent-pending for Tetrahydrocannabinol ( THC ), other psychoactive cannabinoids , non-steroidal anti-inflammatory drugs ( NSAIDs ), nicotine and other molecules .
Lexaria ’ s propiertary technology delivers the following advantages for cannabinoid edibles :
1 ) Masks taste – eliminates the undesired taste in cannabinoid edibles , enabling zero-sugar formats . 2 ) Reduces time of onset – effects are felt within 15-20 min vs . 60-120 min . 3 ) Increases bio-absorption – by 5 – 10X , to equate that of inhalation .
Business Model :
1 ) Out-license ( royalty ) the technology to third-party partners / distributors . Range : 5-10 % of gross sales . Seven deals signed / pending ( 3 definitive agreements , 4 LOI / MOU ’ s pending ).
2 ) Product Sales - Lexaria sells hemp oil CBD ( cannabidiol ) products . Lexaria ’ s branded protein energy bars are excellent for energy , fiber and protein . ViPova™ branded premium teas deliver CBD in several flavors . TurboCBD TM hemp oil capsules are formulated with Ginseng & Ginkgo for enhanced focus and memory .
Patent Portfolio - 19 patent applications filed in US , International ( under the Patent Cooperation Treaty ), and national filings in 44 countries . Patents include both method and composition of matter claims . Patent issued in USA , Australia : “ Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof ”. Additional patent issuances are expected to follow , including THC . Other molecules are also captured within the patent applications and represent future research opportunities . These include : Nicotine , Fat Soluble Vitamins ( e . g ., A , D , K & E ), NSAIDs ( non-steroidal anti-inflammatory drugs such as ibuprofen ).
Collaborative Research Agreement with National Research Council to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions .
Key Executives :
Chris Bunka - Chairman & CEO . Serial entrepreneur , extensive experience in the capital markets , corporate governance , M & A and finance .
John Docherty , M . Sc . - Director & President . 20 yr . senior executive in the pharmaceutical and bioscience M . Sc . in pharmacology and B . Sc . in toxicology from the University of Toronto .
Mr . Ted McKechnie – Director . Senior entrepreneurial executive with extensive senior management & board experience in the consumer goods industry in National and Retail brands . Former President and COO of Maple Leaf Foods .
Stock Information : Trading symbol : CSE : LXX , OTCQB : LXRP Shares o / s : 67m , ( f / d : 79m ) Mgmt & Insiders : 14m ( 21 %) Recent price : C $ 0.42 / US $ 0.35
For more information , contact Alex Blanchard , Communications Manager : ( 778 ) 796-1897 , Email : ABlanchard @ lexariaenergy . com
This Fact Sheet is provided by Lexaria Bioscience Corporation as a convenience for potential investors . More details about the business and its risks can be found in the Company ’ s press releases and filings with the U . S . Securities and Exchange Commission or the Canadian Securities Administrators . This Fact Sheet contains forward-looking statements and actual results may differ materially from such statements . www . lexariabioscience . com Sept 2017